Replies to post #31917 on Intellipharmaceutics International Inc. (IPCI)

[swe77]

The Focalin exclusivity period made it difficult to reverse engineer the Q3 numbers. Focalin had partial exclusivity period during previous quarter which expired at the end of June. I believe the profit sharing % split in June was much higher because of that.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135297600

I was really hoping it would be addressed at the meeting as well as the status of two pending ANDA's (Pristiq & Lamictal).

I guess we could email IPCI and request a breakdown of earnings by product & terms of both deals.

We should be able to reverse engineer the same once we have enough data points.

My new q4 estimate is between 1 and 2 m. I am not sure I understand how the company is planning to attain a cash flow positive status given very low sales.